Improving the quality of human health
Clinical Laboratory Services | Innovative Biomarker and Bioanalytical Solutions
About Synexa Life Sciences
Synexa Life Sciences is a global provider of biomarker and bioanalytical services, specialising in the development, validation, and delivery of a wide range of complex and custom-designed assays. With a team of 150 across five global laboratory locations; Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA), we provide innovative solutions to support our customers to achieve their clinical milestones.
Our main areas of expertise include biomarker identification and development, clinical bioanalysis, soluble biomarker analysis (utilising MSD, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical trials and translational studies.
Services
ProtoTrials®
ProtoTrials® is a proprietary human in vitro translational platform. ProtoTrials studies are adaptive and collaborative in nature and draw together vast scientific expertise, an extensive selection of technologies and customisable assays, along with access to a broad portfolio of samples from both healthy and diseased states.
Expertise
Autoimmune
Synexa specialises in biomarker and bioanalytical services which can be specifically tailored to suit both the modality of the therapeutic and the disease area of focus. Autoimmune conditions are highly heterogenous, affecting numerous cell types, molecular pathways and tissues, necessitating multi-pronged approaches integrating technology platforms including targeted genetic analysis, soluble biomarkers and flow cytometry.
Oncology
Synexa’s expertise in the field of immunology and immune-based analytical technologies makes us the perfect partner in advancing oncology therapeutic pipelines. We use innovative approaches and validated platforms to answer client-specific questions for quality, clinically-relevant data.
Vaccines
Accelerate vaccine development and evaluation with our comprehensive suite of bioanalytical services, supporting safety, immunogenicity, and efficacy assessments for a wide range of vaccine candidates.
Cell & Gene Therapy
Biosimilars
Bridging the gap between science and life.
Discuss real solutions to develop your therapeutic pipeline.
Latest Insights
Cardiovascular complications in chronic kidney disease: New biomarkers and treatment
Individuals with chronic kidney disease (CKD) are at a disproportionately high risk of cardiovascular events. Mechanistically, high salt and water retention cause sympathetic nervous system over reactivity combined with the activation of the renin-angiotensin-aldosterone system (RAAS). Downstream pathophysiological pathways include inflammation, oxidative stress, platelet activation and reduced hormone production, all